ASBMB Annual Meeting

Challenged by a pandemic, Harbig pursues a new approach to treating flu

Meet a JBC Herbert Tabor Early Career Investigator Award winner

When Anne Harbig found out she had won an award for her very first authored paper, she was shocked.

Anne Harbig

"It totally caught me by surprise," Harbig said. The paper was the culmination of all of her data from her Ph.D. research in Eva Böttcher-Friebertshäuser's lab at the Marburg Institute of Virology. "I always wanted to deepen my knowledge about viruses, and I was able to have this great Ph.D. project. I'm very grateful for my supervisor."

Harbig's research takes on the challenge of finding proteases that activate specific strains of influenza, which could be targeted with drugs in order to prevent infection and treat the disease. If inhibiting proteases proves effective in halting influenza infection, these methods could be used to target other enveloped viruses as well, including coronaviruses.

Harbig's project came with all kinds of challenges —wading through piles of transcriptome data, hundreds of in vitro studies with proteases that never activated, and now, the global COVID-19 pandemic that introduced all kinds of disruptions as she continues to pursue the project as a postdoc.

"Sometimes, especially on a Friday when you have the results of the week's experiments and things are not working and everything sucks," she said, "it's good to have the weekend to take a break and have ideas for how to do it differently next week."

To stop flu infection, target host enzymes

Anne Harbig seeks to develop targeted treatments that prevent influenza viruses from entering potential host cells. For a flu infection to begin, the virus must have its surface protein called hemagglutinin cleaved by host enzymes known as proteases.

"A protease is a protein, an enzyme, that cleaves other proteins at specific sites," Harbig explained.

Because the virus cannot enter a cell without a protease present, Harbig and her colleagues are identifying proteases involved in activating certain flu strains so they can develop drugs that can block them.

Harbig used RNA sequencing to search for any segments of mRNA coding for proteases found in the lower respiratory system of mice. Once she identified an array of lung proteases, each one was tested individually for its ability to split apart the hemagglutinin on the surface of influenza B viruses. The proteases that were able to do so were narrowed down further to four candidates that activated influenza B infection in mouse cells.

"The idea is, if we know the protease that activates our virus, we can use protease inhibitors to prevent infection," Harbig said. "If we know all the proteases involved, we can test the inhibitors in murine models, in vivo, and if they work there, then maybe later [we can test them] in human studies."

Harbig has earned her Ph.D. and is continuing to work on the project, hoping to see it reach human clinical trials.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Guananí Gómez–Van Cortright

Guananí Gómez–Van Cortright is a teacher and freelance science writer.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Understanding protein dynamics to design better drugs
Research Spotlight

Understanding protein dynamics to design better drugs

Sept. 21, 2022

C. Denise Okafor is an assistant professor of biochemistry and molecular biology at Penn State and recipient of an NSF CAREER award.

Computation is the new experiment
Annual Meeting

Computation is the new experiment

Sept. 20, 2022

This symposium, Artificial Intelligence and Machine Learning in Structural Biology, Drug Design and Systems Biology. will be part of #DiscoverBMB 2023 in March.

Kuriyan to take over as dean;  Johnson wins Pew scholarship
Member News

Kuriyan to take over as dean; Johnson wins Pew scholarship

Sept. 19, 2022

Awards, promotions, milestones and more. Find out what's going on in the lives of ASBMB members.

'Keep developing your expertise'

'Keep developing your expertise'

Sept. 16, 2022

Anand Balakrishnan is a biochemist at Enanta Pharmaceuticals. He leads a team that has worked on respiratory syncytial virus, SARS-CoV-2 and hepatitis B virus.

Society news briefs: September 2022
Society News

Society news briefs: September 2022

Sept. 15, 2022

If you’re a member, you should be in the know. Find out everything that’s been going on lately with the American Society for Biochemistry and Molecular Biology.

Pipette grant for Whitham; STEAM scholarship for Gandhi
Member News

Pipette grant for Whitham; STEAM scholarship for Gandhi

Sept. 12, 2022

Awards, promotions, milestones and more. Find out what's going on in the lives of ASBMB members.